At Crown Medical Research and Pharmaceutical Science College of Canada, I lead a team developing a 505(b)(1) NDA reconstruction across CTD Modules 1–5. I prepare technical summaries and submission content, and review documents for accuracy and cross-module consistency.
At Sigma Molecules LLC, I developed FDA/EMA CMC regulatory strategy for a manufacturing change and authored approved training modules on change classification, CTD narratives, comparability, and submission strategy. Earlier, at MEYER Organics Private Limited, I reviewed supplier records for cGMP compliance and updated SOPs and templates, contributing to a 20% reduction in review and clearance cycles.

